Navigation Links
Vical Presentation at Military Pandemic Influenza Workshop
Date:11/30/2007

BANGKOK, Nov. 30 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that, by invitation of the U.S. Pacific Command (USPACOM), Larry Smith, Ph.D., Vical's Vice President of Vaccine Research, presented on "DNA Vaccines for Pandemic Influenza" at the USPACOM Pandemic and Avian Influenza Workshop (Bangkok, Thailand -- November 28-30).

U.S. Pacific Command is a unified command, which includes about 300,000 military personnel from the Army, Navy, Air Force, and Marine Corps (about 20 percent of all active-duty U.S. military forces). These forces are in three categories: Forward Deployed (about 100,000), Forward Based and CONUS (Continental U.S.) Based, which comprise the remainder.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring

(858) 646-1127

Website: http://www.vical.com


'/>"/>
SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Vical Names Andrew de Guttadauro Vice President, Corporate Development
2. Vical to Present at Upcoming Investor Conferences
3. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Vical Announces News Release and Conference Call Schedule for Third Quarter 2007 Financial Results
6. Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening
7. Vical to Present at Investor Conferences
8. Amedica Receives FDA 510(k) Clearance for Valeo(TM) Cervical Plate
9. Strategic Diagnostics Updates Roth Conference Presentation Time
10. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
11. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... , ... The need for blood donations in South Texas and across the nation is growing. ... Tissue Center, blood donations are on the decline. In fact, donations across the country are ... in South Texas in the last four years alone. , There is no substitute for ...
(Date:5/23/2016)... , May 23, 2016 Oxitec CEO ... th at 10:15 a.m. ET before the United States ... genetically engineered mosquitos can play in controlling the spread of ... the Zika virus.      (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ... mosquito with a self-limiting gene. Trials in Brazil ...
(Date:5/23/2016)... ... 23, 2016 , ... Foresight Institute , a leading ... for the 2015 Foresight Institute Feynman Prizes. , These prestigious prizes, named ... for experiment and the other for theory in nanotechnology. Prof. Markus J. Buehler, ...
(Date:5/20/2016)... ... 20, 2016 , ... Kablooe Design, a leading provider of product design and ... anniversary of the business. “We have worked hard to build long-term relationships,” says President ... privilege and honor of serving their product design and development needs through the years.” ...
Breaking Biology Technology:
(Date:3/15/2016)... York , March 15, 2016 ... market report published by Transparency Market Research "Digital Door Lock ... and Forecast 2015 - 2023," the global digital door lock ... 731.9 Mn in 2014 and is forecast to grow at ... Growth of micro, small and medium enterprises (MSMEs) across the ...
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... ( http://www.apimages.com ) - Germany . The ... refugee identity cards. DERMALOG will be unveiling this device, and a ... next week.   --> Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ...
(Date:3/9/2016)... YORK , March 9, 2016 This ... and future states of the RNA Sequencing (RNA Seq) ... segments such as instruments, tools and reagents, data analysis, ... Analyze various segments of the RNA-Sequencing market such as ... services Identify the main factors affecting each segment and ...
Breaking Biology News(10 mins):